Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: A raising assembly for use with a gangway connected for rotation between a raised stowed position and a lowered deployed position. The raising assembly comprises at least one fluid actuated cylinder connected to the gangway. A raising actuator is operative to cause operation of the cylinder in a manner that rotates the gangway toward the stowed position while the raising actuator is continuously activated by an operator. A lowering actuator is operative to cause operation of the cylinder in a manner that rotates the gangway toward the deployed position due to gravitational forces while the lowering actuator is continuously activated by the operator. The raising assembly is configured to maintain the gangway at a current position between the stowed position and the deployed position if the operator does one of ceasing to activate the raising actuator while raising the gangway or ceasing to activate the lowering actuator while lowering the gangway.

Abstract: A mouthpiece assembly for an inhalation device including a replaceable substrate component and a replaceable substrate component therefor. The mouthpiece assembly includes a mouthpiece which is essentially a hollow tube within which fluid flow can occur along a substantially longitudinal axis thereof. Within the mouthpiece, a cavity region is formed which is adapted to receive and locate the substantially planar elongated substrate component, such that it interacts with the fluid flow when occurring. The substrate component includes a substrate which can be excited sufficiently to cause aerosolization, and the substrate is fixedly mounted within the substrate component in an orientation and location whereby a channel formation or a conduit of the substrate component at least partially coincides with the cavity region, and thus the surface of the substrate in that cavity region is exposed to, and may be entrained within, whatever fluid may be flowing in that channel or conduit.

Abstract: Described are systems, devices, and methods which related to various aspects of assays for detecting and/or determining a measure of the concentration of analyte molecules or particles in a sample fluid. In some cases, the systems employ an assay consumable comprising a plurality of assay sites. The systems, devices, and/or methods, in some cases, are automated. In some cases, the systems, devices, and/or methods relate to inserting a plurality of beads into assay sites, sealing assay sites, imaging assay sites, or the like.

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: A portable, self-contained beverage apparatus includes a container assembly having a known storage capacity for storing a consumable liquid, and a dispensing assembly disposed within the container assembly that dispenses variable, non-zero quantities of additives into the consumable liquid. The dispensing assembly includes multiple apertures structured and arranged to retain vessels containing the additives to be dispensed into the consumable liquid. The beverage apparatus also includes a level sensor disposed within the container assembly that determines a consumable liquid level of the consumable liquid stored in the container assembly. In certain embodiments, one or more positive displacement pumping mechanisms are configured to pump additive liquid from additive containers into a beverage chamber.

Abstract: Methods, systems, and computer program products are provided that automatically scale an application between private and public cloud computing platforms, while simultaneous enforcing policies ensuring private data is persistently stored on the private cloud computing platform, but not the public cloud computing platform. A traffic manager on the public platform routes traffic to instances of a web app executing on a private platform. A traffic monitor on the private platform monitors performance criteria of the private platform, and reports traffic telemetry to the traffic manager. Based on the traffic telemetry, the traffic manager may instantiate one or more instances of the web app on the public platform to handle traffic. Private data gathered by such instantiated instance(s) is persisted to storage in the private platform, but not in the public platform.

Abstract: A computer-implemented method of computer-implemented method of perceiving structure in a point cloud comprises: applying clustering to the point cloud, and thereby identifying at least one moving object cluster within the point cloud, the point cloud comprising time-stamped points captured over a non-zero accumulation window; determining a motion model for the moving object cluster, by fitting one or more parameters of the motion model to the time-stamped points of that cluster; using the motion model to transform the time-stamped points of the moving object cluster to a common reference time; and applying a perception component to the transformed points of the moving object cluster to extract information about structure exhibited in the transformed points.

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: A method of controlling the generation of an aerosolised composition in an inhalation device having a heater arranged to heat an aerosolisable composition, the method comprising: controlling the power delivered to the heater such that the heater is heated from an ambient temperature to a first temperature, wherein the first temperature is below a temperature at which the aerosolisable composition is aerosolised; delivering a predetermined amount of power to the heater such that the temperature of the heater is increased from the first temperature to a second temperature, wherein the second temperature is greater than or equal to a temperature at which at least a portion of the aerosolisable composition is aerosolised.

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to compounds that inhibit KRas G12D, In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.